Karen Noblett is Chief Medical Officer at Axonics, Inc. (AXNX). They have made 6 open-market trades across 1 company since 2022, most recently 2024-11-15.
CIK 0001756240
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 6 sales. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| AXNX | 45,716 | $3.2M |
Shares reported on the most recent Form 4, priced at the 2024-02-02 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| AXNX | SELL | 2024-01-31 | 2024-02-02 | $67.74 | $1.5M | +0.4% | +0.1% | -0.6% |
| AXNX | SELL · 10b5-1 | 2024-01-08 | 2024-01-10 | $69.00 | $1.1M | -1.2% | -1.4% | -1.7% |
| AXNX | SELL · 10b5-1 | 2023-12-26 | 2023-12-28 | $63.26 | $952K | +8.5% | +7.5% | +8.6% |
| AXNX | SELL | 2023-01-31 | 2023-02-02 | $61.13 | $510K | -6.7% | -7.4% | -15.8% |
| AXNX | SELL | 2022-09-12 | 2022-09-20 | $78.16 | $5.1M | -5.4% | -8.1% | -19.2% |
| AXNX | SELL | 2022-09-07 | 2022-09-09 | $71.53 | $1.5M | -6.1% | -10.8% | -13.9% |
| AXNX | SELL | 2022-03-18 | 2022-03-22 | $57.23 | $1.5M | +10.5% | +7.7% | -14.7% |
| AXNX | SELL | 2022-02-03 | 2022-02-03 | $48.23 | $628K | +13.7% | +13.2% | +20.1% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.